Lupin moves up on getting USFDA`s tentative approval for Enzalutamide Tablets
Lupin is currently trading at Rs. 2362.80, up by 20.65 points or 0.88% from its previous closing of Rs. 2342.15 on the BSE.
The scrip opened at Rs. 2366.35 and has touched a high and low of Rs. 2,371.05 and Rs. 2,344.90 respectively. So far 127 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2492.00 on 07-May-2026 and a 52 week low of Rs. 1838.65 on 06-Aug-2025.
Last one week high and low of the scrip stood at Rs. 2395.00 and Rs. 2,335.40 respectively. The current market cap of the company is Rs. 107090.72 crore.
The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 47.03% and 6.11% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Enzalutamide Tablets, 40 mg, 80 mg, 120 mg, and 160 mg.
The USFDA has tentatively approved Lupin’s Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi Tablets of Astellas for the indication in the approved labeling. While Xtandi Tablets are traditionally available in 40 mg and 80 mg strengths, Lupin’s tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.
